- Home
- PFL vs TERN Comparison
PFL vs TERN Comparison
Compare PFL & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- TERN
- Stock Information
- Founded
- PFL 2003
- TERN 2017
- Country
- PFL United States
- TERN United States
- Employees
- PFL N/A
- TERN N/A
- Industry
- PFL Finance Companies
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PFL Finance
- TERN Health Care
- Exchange
- PFL Nasdaq
- TERN Nasdaq
- Market Cap
- PFL 349.9M
- TERN 310.8M
- IPO Year
- PFL N/A
- TERN 2021
- Fundamental
- Price
- PFL $8.26
- TERN $2.90
- Analyst Decision
- PFL
- TERN Buy
- Analyst Count
- PFL 0
- TERN 5
- Target Price
- PFL N/A
- TERN $15.63
- AVG Volume (30 Days)
- PFL 113.7K
- TERN 1.0M
- Earning Date
- PFL 01-01-0001
- TERN 05-08-2025
- Dividend Yield
- PFL 11.53%
- TERN N/A
- EPS Growth
- PFL N/A
- TERN N/A
- EPS
- PFL N/A
- TERN N/A
- Revenue
- PFL N/A
- TERN N/A
- Revenue This Year
- PFL N/A
- TERN N/A
- Revenue Next Year
- PFL N/A
- TERN N/A
- P/E Ratio
- PFL N/A
- TERN N/A
- Revenue Growth
- PFL N/A
- TERN N/A
- 52 Week Low
- PFL $6.98
- TERN $1.87
- 52 Week High
- PFL $8.62
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PFL 49.75
- TERN 47.68
- Support Level
- PFL $7.73
- TERN $2.93
- Resistance Level
- PFL $8.39
- TERN $3.40
- Average True Range (ATR)
- PFL 0.07
- TERN 0.26
- MACD
- PFL 0.02
- TERN -0.00
- Stochastic Oscillator
- PFL 50.00
- TERN 10.89
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.